[Cardiocirculatory effects of a new sympathomimetic, amezinium methyl sulfate. Results of human pharmacological studies].
Changes in haemodynamic, inotropic state, and myocardial oxygen consumption were investigated in a total of eight patients with coronary artery disease after intravenous injection of 0.07 mg/kg amezinium methyl sulfate (LU 1631, Supratonin). It was demonstrated, that the principal effects of amezinium are consistent with those of a sympathomimetic agent which stimulates vascular alpha- and beta 1-adrenoreceptors. Amezinium (0.07 mg/kg) increased cardiac index, mean arterial pressure and total systemic resistance and dp/dtmax, while there were only minor changes in stroke index, mean pulmonary pressure and total pulmonary vascular resistance. In accordance with the changes in haemodynamics there was a 21.5% increase in myocardial oxygen consumption. But there were no signs of imbalance between oxygen supply and oxygen demand.